# Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

> **NCT01259089** · PHASE1,PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 38 (actual)

## Conditions studied

- Adenocarcinoma of the Lung
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** Hsp90 inhibitor AUY922
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** needle biopsy
- **GENETIC:** mutation analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01259089
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-27
- **Primary completion:** 2013-06-04
- **Final completion:** 2014-09-29
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2019-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01259089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01259089, "Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01259089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*